Back to Browse Journals » Vascular Health and Risk Management » Volume 4 » Issue 3

Antiplatelet drugs in cardiological practice: Established strategies and new developments

Authors Florian Krötz, Hae-Young Sohn, Volker Klauss

Published Date June 2008 Volume 2008:4(3) Pages 637—645

DOI http://dx.doi.org/10.2147/VHRM.S2691

Published 30 June 2008

Florian Krötz, Hae-Young Sohn, Volker Klauss

Cardiology, Medical Policlinic, Ludwig-Maximilians-Universität, Ziemssenstr. 1, 80336 München

Abstract: A common pathophysiological course in vascular diseases is an overwhelming activation and aggregation of blood platelets, which results in atherothrombosis. By causing the last decisive step of cerebral, coronary, or peripheral arterial ischemia thrombotic complications of atherosclerotic disease represent a major player in death cause statistics of most western countries. The development of novel therapies against platelet-dependent thrombosis and the concurrent improvement of existing therapeutic strategies thus is a paramount focus of pharmaceutical research. Currently, efficiency, dosing and indications of established antiplatelet substances are being re-evaluated, whilst new, so far unrecognized molecular targets for inhibition of platelet activity come up front. This not only allows for interesting new therapeutical options, but also widens our insight into the role platelets play in atherosclerosis in general. This article summarizes the relevant pathophysiology of platelet activation, presents current concepts in antiplatelet drug therapy, and highlights the role of platelets in vascular diseases apart from atherothrombosis.

Keywords: atherothrombosis, antiplatelet drug therapy, pathophysiology, platelet activation

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Disruption of human papillomavirus 16 E6 gene by clustered regularly interspaced short palindromic repeat/Cas system in human cervical cancer cells [Corrigendum]

Yu L, Wang XL, Zhu D, Ding WC, Wang LM, Zhang CL, Jiang XH, Shen H, Liao SJ, Ma D, Hu Z, Wang H

OncoTargets and Therapy 2015, 8:365-366

Published Date: 4 February 2015

Novel drug-eluting stents in the treatment of de novo coronary lesions

Davide Capodanno, Fabio Dipasqua, Corrado Tamburino

Vascular Health and Risk Management 2011, 7:103-118

Published Date: 25 February 2011

The influence of polymorbidity, revascularization, and wound therapy on the healing of arterial ulceration

Joerg Tautenhahn, Ralf Lobmann, Brigitte Koenig, Zuhir Halloul, Hans Lippert, Thomas Buerger

Vascular Health and Risk Management 2008, 4:683-689

Published Date: 30 June 2008

Adherence treatment factors in hypertensive African American women

Marie N Fongwa, Lorraines S Evangelista, Ron D Hays, David S Martins, David Elashoff, et al

Vascular Health and Risk Management 2008, 4:157-166

Published Date: 6 March 2008

Are pleiotropic effects of statins real?

Alberto Corsini, Nicola Ferri, Michele Cortellaro

Vascular Health and Risk Management 2007, 3:611-613

Published Date: 20 November 2007

Secular trends in lipid-lowering treatment and lipid levels after a first acute myocardial infarction

Lena Björck, Catharina Welin, Annika Rosengren

Vascular Health and Risk Management 2007, 3:1045-1051

Published Date: 15 January 2007

Leptin and hypertension in obesity

Paco E Bravo, Stephen Morse, David M Borne, Erwin A Aguilar, Efrain Reisin

Vascular Health and Risk Management 2006, 2:163-169

Published Date: 25 January 2006

Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome

Hadi AR Hadi, Cornelia S Carr, Jassim Al Suwaidi

Vascular Health and Risk Management 2005, 1:183-198

Published Date: 29 January 2005

Utility of ranolazine in chronic stable angina patients

Pawan D Patel, Rohit R Arora

Vascular Health and Risk Management 2008, 4:819-824

Published Date: 30 November 1999